<DOC>
	<DOCNO>NCT00002391</DOCNO>
	<brief_summary>To compare safety , tolerance , durability viral load response antiviral activity 1592U89/zidovudine ( ZDV ) /lamivudine ( 3TC ) regimen vs. ZDV/3TC regimen . To determine clinical efficacy two regimen measure survival , disease progression , weight growth velocity , neuropsychological neurological change . To assess development viral resistance relative pharmacokinetics associate regimen .</brief_summary>
	<brief_title>The Safety Effectiveness Zidovudine Plus Lamivudine , Used With Without 1592U89 , HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs</brief_title>
	<detailed_description>Patients randomize receive blind treatment ZDV/3TC alone combination 1592U89 , orally 16 week . If 16-week period certain criterion meet , patient may option switch open-label treatment remainder study period .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Intravenous immunoglobulin G , erythropoietin , GCSF GMCSF . Opportunistic infection prophylaxis . Patients must : HIV1 infection document : &lt; 18 month age : one positive viral test culture one positive viral test ( culture , PCR , p24 antigen , Immune Complex Dissociation p24 antigen ) two different specimen . &gt; = 18 month age : two positive viral test state , one may determine federally document ELISA confirm Western blot Indirect Fluorescent Antibody test . Any CDC Categories : 1 , 2 , 3 , N , A , B , C 1994 Revised Classification System HIV Infection Children Less 13 Years Age . CD4+ count &gt; = 15 % within 14 day prior study drug administration . No active ongoing AIDSdefining opportunistic infection precludes absorption study drug observation study parameter . Signed , inform consent parent legal guardian patient 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Serious bacterial infection precludes absorption study drug observation study parameter . Documented hypersensitivity nucleoside analog . Coenrollment certain opportunistic infection protocol exclusionary approval obtain . Malignancy . Lifethreatening infection chronic disease may compromise patient safety . Grade 3/4 clinical laboratory toxicity current grade 2 high pancreatic amylase lipase toxicity define ACTG Toxicity Tables within 14 day prior study entry . Concurrent Medication : Excluded : Other antiHIV therapy . Probenecid . Biologic response modifier ( unless list included concurrent medication ) megestrol acetate . Human growth hormone . Immunomodulators cytotoxic chemotherapeutic agent . Systemic corticosteroid &gt; 14 day without approval . Investigational agent . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : History clinically relevant pancreatitis hepatitis within past 6 month . Participation vaccine trial . Prior Medication : Excluded : Protease inhibitor therapy within 2 week prior randomization . Interleukins interferon within 30 day prior study drug administration . Investigational drug within 14 day prior randomization . HIV vaccine dose within past 30 day . Required : &gt; 12 week prior antiretroviral therapy unchanged therapy 12 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Child Development</keyword>
	<keyword>abacavir</keyword>
</DOC>